Joseph H. Boccuzi Appointed to Allergan plc Board of Directors

DUBLIN, July 19, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Joseph H. Boccuzi has been appointed to its Board of Directors, effective immediately.  Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

"Talented people give Allergan an edge as we continue to build our Bold culture and drive long-term sustainable growth," said Brent Saunders, Chairman and Chief Executive Officer of Allergan. "Joe Boccuzi has a long track record of identifying great life sciences leaders globally and successfully matching board-level and executive talent with companies to drive long-term value."

"Our Board believes that one of its key roles is to oversee development of organizational capabilities, and to focus on talent management.  Joe Boccuzi's unique insights, leadership skills and experience are additive and complementary to the diverse mix of professional experiences of our board of directors," said Chris Coughlin, Lead Independent Director. "I welcome Joe to our board and look forward to his contributions as we work together to advance the interests of Allergan shareholders."

"I was drawn to the Allergan board by its adroit, forward-thinking and dynamic leadership team and Board of Directors. It is an exciting time to join Allergan, and I look forward to helping the Company achieve its full potential for shareholders and society," said Boccuzi.

Mr. Boccuzi retired from Spencer Stuart in December 2016, after 24 years of service, where he played a central role in establishing and building the firm's Life Sciences Practice.  He served in positions of increasing responsibility within Spencer Stuart, most recently as a Partner in the firm's Global Life Sciences, Board and Chief Executive Officer Practices.

Prior to joining Spencer Stuart, Mr. Boccuzi worked in executive search, venture capital and corporate management roles.  He served as a consultant with Paul R. Ray & Company, an executive search firm.  Prior to that, he worked as a Financial Advisor for Merrill Lynch.  Mr. Boccuzi also held several leadership positions at National Patent Development Corporation, a venture capital firm specializing in medical technology and investment throughout the U.S. and worldwide.  While there, he managed four medical startup operations serving as chief operating officer, board member and adviser to the board of directors.  Prior to that, Mr. Boccuzi worked in sales for Xerox Corporation.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      
Allergan:
Investors:
Daphne Karydas
(862) 261-8006

Media:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc

Related Links

http://www.allergan.com